Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
Stevens-Johnson syndrome
cyclosporine
pembrolizumab
toxic epidermal necrolysis
Journal
Rhode Island medical journal (2013)
ISSN: 2327-2228
Titre abrégé: R I Med J (2013)
Pays: United States
ID NLM: 101605827
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Adverse cutaneous reactions associated with the immune checkpoint inhibitor (ICI) pembrolizumab are well documented, yet life-threatening reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are infrequent.1,2 We present a case of pembrolizumab-induced TEN in a patient with metastatic esophageal adenocarcinoma who was successfully treated with cyclosporine and systemic corticosteroids.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
pembrolizumab
DPT0O3T46P
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-36Subventions
Organisme : NIAID NIH HHS
ID : R25 AI140490
Pays : United States
Références
J Invest Dermatol. 2000 Aug;115(2):149-53
pubmed: 10951229
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
JAAD Case Rep. 2020 Apr 29;6(5):400-402
pubmed: 32382629
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268
pubmed: 32454097
Ann Oncol. 2015 Dec;26(12):2375-91
pubmed: 26371282
Br J Dermatol. 2010 Oct;163(4):847-53
pubmed: 20500799
J Oncol Pharm Pract. 2020 Jul;26(5):1259-1265
pubmed: 31810421
J Invest Dermatol. 2018 Jun;138(6):1293-1300
pubmed: 29369774